The emerging class of amyloid-targeting therapies (ATTs) are at the forefront of innovative approaches that promise to alter the course of Alzheimer’s disease (AD). However, the translation of these scientific advancements into clinical practice necessitates a well-informed clinical workforce adept …
Alzheimer’s disease (AD) presents a growing challenge in contemporary health care, with escalating prevalence and a significant burden imposed on patients, families, and health care systems globally. Early and accurate diagnosis of AD is essential for effective support and treatment. …
The Food and Drug Administration (FDA) recently approved immune checkpoint inhibitors (ICIs) for patients with advanced or recurrent endometrial cancer (EC) who did not respond to first-line treatment with chemotherapy. This led to several new trials of emerging therapies, including …
Studies demonstrate that approximately 65%-82% of patients with Crohn’s disease (CD) report at least some degree of bowel urgency, but this symptom is largely underrecognized by gastroenterologists and health care professionals (HCPs) caring for patients with inflammatory bowel disease (IBD). …
Chronic kidney disease (CKD) is a common comorbidity among patients with non-valvular atrial fibrillation (NVAF) and/or venous thromboembolism (VTE). Paradoxically, declining kidney function increases both thromboembolic and bleeding risks in patients with these conditions, requiring a fragile balance when implementing …
Anticoagulation for renally-impaired individuals with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) often entails balancing the risk of vascular events (e.g., stroke, pulmonary embolism) with the dangers of excess bleeding. In this CME Outfitters BriefCase series, two expert clinicians …
Patients and health care professionals (HCPs) face additional challenges when the treatments prescribed for pain management (e.g., opioids) lead to substance use problems. HCPs must then re-evaluate treatment plans for acute, subacute, and chronic pain and encourage treatment for opioid …
Recently, interleukin (IL)-23 and the inflammatory IL-23/T-helper (Th)-17 axis have been identified as central drivers of inflammation related to inflammatory bowel disease (IBD). Science in the field of cytokine-targeting therapies, specifically in the field of IL-23 P19 targeting agents, is …
Despite advances in the treatment and management of dermatologic conditions such as psoriasis, significant disparities in both treatment and outcomes persist for patients from racial/ethnic underserved groups. Patients of color are not only more likely to present with more severe …